BIT:1ABBV - Euronext Milan - US00287Y1091 - Common Stock - Currency: EUR
BIT:1ABBV (3/5/2025, 7:00:00 PM)
194
-7.25 (-3.6%)
The current stock price of 1ABBV.MI is 194 EUR. In the past month the price increased by 18.15%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.96 | 346.68B | ||
AMG.DE | AMGEN INC | 16.35 | 161.21B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.55 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.27 | 134.47B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 252.45 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.2 | 20.54B | ||
0QF.DE | MODERNA INC | N/A | 13.19B | ||
1MRNA.MI | MODERNA INC | N/A | 12.31B | ||
BIO.DE | BIOTEST AG | 23.98 | 1.62B | ||
GLPG.AS | GALAPAGOS NV | 7.83 | 1.61B |
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 50000
Company Website: https://www.abbvie.com/
Investor Relations: https://investors.abbvie.com
Phone: 18479327900
The current stock price of 1ABBV.MI is 194 EUR. The price decreased by -3.6% in the last trading session.
The exchange symbol of ABBVIE INC is 1ABBV and it is listed on the Euronext Milan exchange.
1ABBV.MI stock is listed on the Euronext Milan exchange.
33 analysts have analysed 1ABBV.MI and the average price target is 201 EUR. This implies a price increase of 3.61% is expected in the next year compared to the current price of 194. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABBVIE INC (1ABBV.MI) has a market capitalization of 342.48B EUR. This makes 1ABBV.MI a Mega Cap stock.
ABBVIE INC (1ABBV.MI) currently has 50000 employees.
The Revenue of ABBVIE INC (1ABBV.MI) is expected to grow by 6.04% in the next year. Check the estimates tab for more information on the 1ABBV.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABBVIE INC (1ABBV.MI) has a dividend yield of 3.11%. The yearly dividend amount is currently 5.75. Check the full fundamental report for a detailed analysis of 1ABBV.MI dividend history, reliability and sustainability.
ABBVIE INC (1ABBV.MI) will report earnings on 2025-04-24, before the market open.
The PE ratio for ABBVIE INC (1ABBV.MI) is 20.7. This is based on the reported non-GAAP earnings per share of 9.37 and the current share price of 194 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1ABBV.MI.
ChartMill assigns a technical rating of 4 / 10 to 1ABBV.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1ABBV.MI. 1ABBV.MI has an excellent profitability rating, but there are concerns on its financial health.
Over the last trailing twelve months 1ABBV.MI reported a non-GAAP Earnings per Share(EPS) of 9.37. The EPS decreased by -8.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 9.15% | ||
ROA | 3.54% | ||
ROE | 84.23% | ||
Debt/Equity | 9.7 |
ChartMill assigns a Buy % Consensus number of 80% to 1ABBV.MI. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 23.75% and a revenue growth 6.04% for 1ABBV.MI